Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Net Income towards Common Stockholders (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Net Income towards Common Stockholders over the past 3 years, most recently at -$46.9 million for Q4 2025.

  • Quarterly results put Net Income towards Common Stockholders at -$46.9 million for Q4 2025, down 112.19% from a year ago — trailing twelve months through Dec 2025 was -$124.0 million (up 4.63% YoY), and the annual figure for FY2025 was -$124.0 million, up 4.63%.
  • Net Income towards Common Stockholders for Q4 2025 was -$46.9 million at Tonix Pharmaceuticals Holding, down from -$32.0 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for TNXP hit a ceiling of -$14.2 million in Q3 2024 and a floor of -$78.8 million in Q2 2024.
  • Median Net Income towards Common Stockholders over the past 3 years was -$28.1 million (2023), compared with a mean of -$30.9 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: plummeted 177.81% in 2024 and later skyrocketed 64.11% in 2025.
  • Tonix Pharmaceuticals Holding's Net Income towards Common Stockholders stood at -$27.3 million in 2023, then grew by 19.08% to -$22.1 million in 2024, then tumbled by 112.19% to -$46.9 million in 2025.
  • The last three reported values for Net Income towards Common Stockholders were -$46.9 million (Q4 2025), -$32.0 million (Q3 2025), and -$28.3 million (Q2 2025) per Business Quant data.